Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BLASST-1 (Bladder Cancer Signal Seeking Trial): Phase II Trial of Neoadjuvant Nivolumab With Cisplatin and Gemcitabine in Muscle-Invasive Bladder Cancer (MIBC) Patients Undergoing Radical Cystectomy

Next Previous
X
Search
Trial Profile

BLASST-1 (Bladder Cancer Signal Seeking Trial): Phase II Trial of Neoadjuvant Nivolumab With Cisplatin and Gemcitabine in Muscle-Invasive Bladder Cancer (MIBC) Patients Undergoing Radical Cystectomy

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 06 Mar 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cisplatin (Primary) ; Gemcitabine (Primary) ; Nivolumab (Primary)
  • Indications Bladder cancer; Carcinoma
  • Focus Therapeutic Use
  • Acronyms BLASST-1

    • Most Recent Events

    • 27 Jan 2024 Results (n=34) assessing the the ability of the AI model to identify non-responders to neoadjuvant chemo-immunotherapy. in the BLASST-1 cohort based on computerized image features of nuclear morphology and architecture on pre-treatment transurethral resection of bladder tumor (TURBT) tissues, presented at the 2024 Genitourinary Cancers Symposium.
    • 18 Feb 2023 Results evaluating correlation of PaR with tumor mutation patterns of responders (R) and non-responders (NR) using Whole Genome Sequencing (WGS) presented at the 2023 Genitourinary Cancers Symposium.
    • 01 Feb 2023 According to a Veracyte media release, data from this trial will be presented at the 2023 ASCO Genitourinary (GU) Cancers Symposium 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top